Xspray Pharma AB (publ) (LON:0GHZ)

Market Cap	50.92M -64.3%
Revenue (ttm)	191.77K
Net Income	-12.40M
EPS	-0.30
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,779
Open	13.78
Previous Close	n/a
Day's Range	13.60 - 13.82
52-Week Range	13.60 - 61.40
Beta	0.82
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partn...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 24
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GHZ

Financial Performance

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 12, 2026

Data Sources Report a data error